
Akash Saxena
Examiner (ID: 18141, Phone: (571)272-8351 , Office: P/2128 )
| Most Active Art Unit | 2128 |
| Art Unit(s) | 2147, 2188, 2128 |
| Total Applications | 658 |
| Issued Applications | 275 |
| Pending Applications | 87 |
| Abandoned Applications | 305 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19387810
[patent_doc_number] => 20240277680
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA
[patent_app_type] => utility
[patent_app_number] => 18/615334
[patent_app_country] => US
[patent_app_date] => 2024-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21070
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18615334
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/615334 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA | Mar 24, 2024 | Pending |
Array
(
[id] => 19332542
[patent_doc_number] => 20240246972
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => AZAINDOLE ROCK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/610041
[patent_app_country] => US
[patent_app_date] => 2024-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31926
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18610041
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/610041 | Azaindole rock inhibitors | Mar 18, 2024 | Issued |
Array
(
[id] => 19784154
[patent_doc_number] => 20250057833
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-20
[patent_title] => METHODS OF TREATING PSYCHIATRIC DISORDERS IN OBESE PATIENTS WITH BREXPIPRAZOLE
[patent_app_type] => utility
[patent_app_number] => 18/596840
[patent_app_country] => US
[patent_app_date] => 2024-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22494
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 137
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18596840
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/596840 | METHODS OF TREATING PSYCHIATRIC DISORDERS IN OBESE PATIENTS WITH BREXPIPRAZOLE | Mar 5, 2024 | Pending |
Array
(
[id] => 19343541
[patent_doc_number] => 20240252504
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/596553
[patent_app_country] => US
[patent_app_date] => 2024-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89429
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18596553
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/596553 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | Mar 4, 2024 | Pending |
Array
(
[id] => 19571805
[patent_doc_number] => 20240376097
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => BCL-2 Inhibitor
[patent_app_type] => utility
[patent_app_number] => 18/593497
[patent_app_country] => US
[patent_app_date] => 2024-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 107776
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593497
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/593497 | BCL-2 Inhibitor | Feb 29, 2024 | Abandoned |
Array
(
[id] => 19248556
[patent_doc_number] => 20240199543
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same
[patent_app_type] => utility
[patent_app_number] => 18/443025
[patent_app_country] => US
[patent_app_date] => 2024-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23297
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443025
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443025 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | Feb 14, 2024 | Pending |
Array
(
[id] => 19310746
[patent_doc_number] => 12036540
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-07-16
[patent_title] => Selective hydrogenation catalyst of a,b-unsaturated ketone using electronically weakly coupled 4,4'-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(2-mercaptopyridine)(P
[patent_app_type] => utility
[patent_app_number] => 18/436396
[patent_app_country] => US
[patent_app_date] => 2024-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 5
[patent_no_of_words] => 3596
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436396
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/436396 | Selective hydrogenation catalyst of a,b-unsaturated ketone using electronically weakly coupled 4,4'-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(2-mercaptopyridine)(P | Feb 7, 2024 | Issued |
Array
(
[id] => 19332532
[patent_doc_number] => 20240246962
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => HETEROCYCLIC GLP-1 AGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/424580
[patent_app_country] => US
[patent_app_date] => 2024-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53345
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18424580
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/424580 | Heterocyclic GLP-1 agonists | Jan 25, 2024 | Issued |
Array
(
[id] => 19332531
[patent_doc_number] => 20240246961
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => AUTOTAXIN INHIBITOR COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/420609
[patent_app_country] => US
[patent_app_date] => 2024-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51269
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420609
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/420609 | AUTOTAXIN INHIBITOR COMPOUNDS | Jan 22, 2024 | Pending |
Array
(
[id] => 19263558
[patent_doc_number] => 20240207255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/419894
[patent_app_country] => US
[patent_app_date] => 2024-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45903
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18419894
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/419894 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | Jan 22, 2024 | Pending |
Array
(
[id] => 19332531
[patent_doc_number] => 20240246961
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => AUTOTAXIN INHIBITOR COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/420609
[patent_app_country] => US
[patent_app_date] => 2024-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51269
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420609
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/420609 | AUTOTAXIN INHIBITOR COMPOUNDS | Jan 22, 2024 | Pending |
Array
(
[id] => 19263558
[patent_doc_number] => 20240207255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/419894
[patent_app_country] => US
[patent_app_date] => 2024-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45903
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18419894
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/419894 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | Jan 22, 2024 | Pending |
Array
(
[id] => 19248563
[patent_doc_number] => 20240199550
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL
[patent_app_type] => utility
[patent_app_number] => 18/416741
[patent_app_country] => US
[patent_app_date] => 2024-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22629
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -109
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18416741
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/416741 | SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL | Jan 17, 2024 | Pending |
Array
(
[id] => 19248563
[patent_doc_number] => 20240199550
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL
[patent_app_type] => utility
[patent_app_number] => 18/416741
[patent_app_country] => US
[patent_app_date] => 2024-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22629
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -109
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18416741
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/416741 | SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL | Jan 17, 2024 | Pending |
Array
(
[id] => 19586332
[patent_doc_number] => 20240383889
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/545201
[patent_app_country] => US
[patent_app_date] => 2023-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18545201
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/545201 | Pyrazolopyridine compounds and uses thereof | Dec 18, 2023 | Issued |
Array
(
[id] => 19265294
[patent_doc_number] => 20240208993
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/544546
[patent_app_country] => US
[patent_app_date] => 2023-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41862
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18544546
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/544546 | Five- and six-membered compound, and preparation method therefor and pharmaceutical composition and use thereof | Dec 18, 2023 | Issued |
Array
(
[id] => 19586332
[patent_doc_number] => 20240383889
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/545201
[patent_app_country] => US
[patent_app_date] => 2023-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18545201
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/545201 | Pyrazolopyridine compounds and uses thereof | Dec 18, 2023 | Issued |
Array
(
[id] => 19090948
[patent_doc_number] => 11952378
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-04-09
[patent_title] => Pyrrolo[2,3-c]isoquinoline-1,2-dione compounds as CK2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/539771
[patent_app_country] => US
[patent_app_date] => 2023-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9456
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18539771
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/539771 | Pyrrolo[2,3-c]isoquinoline-1,2-dione compounds as CK2 inhibitors | Dec 13, 2023 | Issued |
Array
(
[id] => 19731095
[patent_doc_number] => 12209086
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-28
[patent_title] => FGFR3 inhibitor compounds
[patent_app_type] => utility
[patent_app_number] => 18/538505
[patent_app_country] => US
[patent_app_date] => 2023-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58485
[patent_no_of_claims] => 44
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18538505
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/538505 | FGFR3 inhibitor compounds | Dec 12, 2023 | Issued |
Array
(
[id] => 19299916
[patent_doc_number] => 20240228485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-11
[patent_title] => SOLID FORMS OF EMETINE
[patent_app_type] => utility
[patent_app_number] => 18/537371
[patent_app_country] => US
[patent_app_date] => 2023-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18537371
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/537371 | SOLID FORMS OF EMETINE | Dec 11, 2023 | Issued |